CY1111063T1 - Καθολικος οδηγος gas1 - Google Patents

Καθολικος οδηγος gas1

Info

Publication number
CY1111063T1
CY1111063T1 CY20101101090T CY101101090T CY1111063T1 CY 1111063 T1 CY1111063 T1 CY 1111063T1 CY 20101101090 T CY20101101090 T CY 20101101090T CY 101101090 T CY101101090 T CY 101101090T CY 1111063 T1 CY1111063 T1 CY 1111063T1
Authority
CY
Cyprus
Prior art keywords
heavy chain
chain variable
variable domain
immunoglobulin heavy
domain polypeptide
Prior art date
Application number
CY20101101090T
Other languages
English (en)
Inventor
Wildt Rudolph M T De
Original Assignee
Domantis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Limited filed Critical Domantis Limited
Publication of CY1111063T1 publication Critical patent/CY1111063T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gas Separation By Absorption (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Αποκαλύπτεται ένα πολυνουκλεοτιδικό μόριο που αποτελείται από έναν υποκινητή που συνδέεται λειτουργικά με μια αλληλουχία νουκλεϊνικού οξέος που κωδικοποιεί ένα σηματοδοτικό πεπτίδιο έκκρισης GAS1, όπου ο αναφερόμενος υποκινητής δεν είναι υποκινητής ραμνόζης.
CY20101101090T 2004-03-24 2010-11-29 Καθολικος οδηγος gas1 CY1111063T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576404P 2004-03-24 2004-03-24
EP05729650A EP1737962B1 (en) 2004-03-24 2005-03-24 Gas1 universal leader

Publications (1)

Publication Number Publication Date
CY1111063T1 true CY1111063T1 (el) 2015-06-11

Family

ID=34963448

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101090T CY1111063T1 (el) 2004-03-24 2010-11-29 Καθολικος οδηγος gas1

Country Status (11)

Country Link
US (1) US7846721B2 (el)
EP (2) EP2172553A1 (el)
AT (1) ATE479760T1 (el)
CY (1) CY1111063T1 (el)
DE (1) DE602005023291D1 (el)
DK (1) DK1737962T3 (el)
ES (1) ES2351509T3 (el)
PL (1) PL1737962T3 (el)
PT (1) PT1737962E (el)
SI (1) SI1737962T1 (el)
WO (1) WO2005093074A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005311099B2 (en) 2004-12-02 2012-02-02 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
SG194383A1 (en) 2008-12-05 2013-11-29 Glaxo Group Ltd Methods for selecting protease resistant polypeptides
SG173489A1 (en) 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
CN102405232B (zh) 2009-02-19 2015-08-19 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
EA022925B1 (ru) 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
CA2768462A1 (en) 2009-07-16 2011-01-20 Glaxo Group Ltd. Improved anti-serum albumin binding single variable domains
EP2453920A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
BR112012001977A2 (pt) 2009-07-29 2017-01-31 Glaxo Group Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar.
WO2011086143A2 (en) 2010-01-14 2011-07-21 Glaxo Group Limited Liver targeting molecules
EP2560992A2 (en) 2010-04-21 2013-02-27 Glaxo Group Limited Binding domains
US9040668B2 (en) 2010-05-20 2015-05-26 Glaxo Group Limited Anti-serum albumin binding variants
EP2603607B1 (en) * 2010-08-11 2016-04-06 Celula, Inc. Genotyping dna
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
KR20130055663A (ko) 2010-08-20 2013-05-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 개선된 항-혈청 알부민 결합 변이체
JP6062375B2 (ja) 2011-01-06 2017-01-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド
JP2014505698A (ja) 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
MY165090A (en) 2011-04-21 2018-02-28 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40
CA2877009C (en) * 2012-07-05 2023-10-03 Devin TESAR Expression and secretion system
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression

Also Published As

Publication number Publication date
US20070026462A1 (en) 2007-02-01
EP1737962A1 (en) 2007-01-03
US7846721B2 (en) 2010-12-07
DK1737962T3 (da) 2010-12-13
DE602005023291D1 (de) 2010-10-14
EP2172553A1 (en) 2010-04-07
ES2351509T3 (es) 2011-02-07
SI1737962T1 (sl) 2011-01-31
WO2005093074A1 (en) 2005-10-06
PL1737962T3 (pl) 2011-02-28
EP1737962B1 (en) 2010-09-01
PT1737962E (pt) 2010-12-03
ATE479760T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
CY1111063T1 (el) Καθολικος οδηγος gas1
NZ734307A (en) Antibodies specific for claudin 6 (cldn6)
DK1831362T3 (da) Syreaktive svampeproteaser
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
ATE477336T1 (de) Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung
JP2014061000A5 (el)
MX337991B (es) Metodo para detectar cancer.
HK1097855A1 (en) Method of detecting probnp with a monoclonal antibody binding to the amino acid 41-46
ATE402267T1 (de) Verfahren zur herstellung von monoklonalen antikörpern
BRPI0716997B8 (pt) proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma
DE502006009060D1 (de) Verfahren zur fermentativen Herstellung von Antikörpern
DK1716178T3 (da) Mindre immunogene bindingsmolekyler
ATE513788T1 (de) Verfahren zur reinigung von lithiumsulfid
ATE514717T1 (de) Rekombinante produktion von antikörpermischungen
NZ592308A (en) Non-human mammals for the production of chimeric antibodies
WO2006116657A3 (en) Single-chain antibody with cleavable linker
ATE441715T1 (de) Streptococcus pyogenes antigene
DE602005016818D1 (de) Verfahren zur charakterisierung einer polyklonalen zellinie
WO2004099376A3 (en) Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
DK1609863T3 (da) Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
ATE525642T1 (de) Sensoranordnung und herstellungsverfahren für einen durch kapillareffekt gefüllten diagnose- sensor
ATE537133T1 (de) Verfahren zur herstellung von olefin
DE60232346D1 (de) Verfahren zur weithin ungestützten verbrennung von petroleumkoks